CSIMarket
 
Hillevax Inc   (HLVX)
Other Ticker:  
 
 
Price: $18.0000 $0.30 1.695%
Day's High: $18.18 Week Perf: -0.66 %
Day's Low: $ 17.01 30 Day Perf: 20 %
Volume (M): 245 52 Wk High: $ 20.22
Volume (M$): $ 4,405 52 Wk Avg: $14.68
Open: $17.72 52 Wk Low: $9.94



 Market Capitalization (Millions $) 703
 Shares Outstanding (Millions) 39
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -108
 Cash Flow (TTM) (Millions $) -84
 Capital Exp. (TTM) (Millions $) 14

Hillevax Inc
Hillevax Inc is a technology company specializing in the development and manufacture of innovative healthcare solutions. The company focuses on researching, designing, and producing medical devices, pharmaceuticals, and biotechnology products to address various medical conditions and improve patient outcomes. Hillevax Inc has a reputation for its dedication to scientific research, commitment to quality, and staying at the forefront of technological advancements in the healthcare industry.


   Company Address: 321 Harrison Avenue Boston 2118 MA
   Company Phone Number: 213-5054   Stock Exchange / Ticker: NASDAQ HLVX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Licensing Agreement

Norovirus No More: HilleVax and Kangh's Groundbreaking Collaboration Steers Vaccine Development into the Future

Published Mon, Jan 8 2024 12:01 PM UTC

The ever-prevalent norovirus, notorious for wreaking havoc on our gastrointestinal system, may soon meet its match. HilleVax and Kangh's recent exclusive license agreement for the Hexavalent VLP Norovirus Vaccine Candidate outside of China marks a significant milestone in the battle against this highly contagious and debilitating illness. In this article, we will delve into ...

Hillevax Inc

Hillevax Inc Plunges Further: Alarming Deterioration in Business Results Amid Financial Turmoil, September 30th, 2023

Hillevax Inc, a clinical-stage biopharmaceutical company, recently reported its operating loss for the third quarter of 2023. The company disclosed an operating loss of $-33.911 million, which is a significant increase compared to the loss of $-17.892 million in the third quarter of 2022. This raises concerns among market observers about whether Hillevax will be able to generate revenue in the near future.
To address this issue, the company's Chief Financial Officer (CFO) is implementing distinct corporate policies aimed at securing consistent revenue sources. However, despite these efforts, Hillevax Inc has encountered shortfalls totaling $-31.815 million, which is a significant increase from the $-16.805 million reported for the same period last year.

Shares

HilleVax, a Leading Biopharmaceutical Firm, Set to Raise $100 Million in an Underwritten Public Offering to Fuel Vaccine Development and Commercialization

Published Tue, Sep 19 2023 8:10 PM UTC

HilleVax, a Promising Player in the Biopharmaceutical Industry, Seeks to Raise $100 Million in an Underwritten Public Offering
Boston, September 19, 2023 - HilleVax, Inc. (Nasdaq: HLVX), a distinguished clinical-stage biopharmaceutical company, has recently made a significant announcement regarding its plans to offer and sell $100.0 million of its common stock in an unde...

Hillevax Inc

Leading Biotech & Pharma Company, Hillevax Inc, Executes Effective Measures to Improve Financial Position; Revenue Adjustments Raise Investor Questions



Hillevax Inc, a leading company in its industry, recently released its financial results for the April to June 30, 2023, time-frame. These results highlight notable adjustments in revenue and operating deficit as compared to the same period last year. Additionally, the company's management has demonstrated effective measures to improve its financial position. This article explores the implications of these results and how they are likely to impact Hillevax Inc moving forward.
1. Revenue Adjustments and Investor Sentiment:
Throughout the earnings season of April to June 30, 2023, investors did not consider certain revenue adjustments made by Hillevax Inc. While the specific adjustments are not mentioned, this suggests that the reported revenue figure might not accurately reflect the company's true financial performance. Uncertainty regarding the nature of these adjustments could potentially affect investor sentiment and raise questions about the company's accounting practices.

Hillevax Inc

Hillevax Inc Faces Financial Turmoil as Existing Costs Escalate in Recent Fiscal Period

Hillevax Inc seems to hit a rough patch of financial turmoil, recording a cumulative net loss of $-119 million during the 12 months ending in the first quarter of 2023. The net loss resulted in a negative return on investment (ROI) of -38.7%, a significantly low return that is enough to raise red flags among investors.
Furthermore, within the Healthcare sector, a total of 370 other companies had a higher return on investment than Hillevax. This suggests that the company is lagging behind its competitors and is struggling to keep up with the industry's standards.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com